Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors
(ST) and hematological malignancies. We summarized the CD47-related clinical research …

CD47 is an immunoglobulin that is overexpressed on the surface of many types of cancer
cells. CD47 forms a signaling complex with signal-regulatory protein α (SIRPα), enabling the …

Synthetic biology is driving a new era of medicine through the genetic programming of living
cells,. This transformative approach allows for the creation of engineered systems that …

Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …

The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …

WNT/β-catenin signaling is involved in many physiological processes. Its implication in
embryonic development, cell migration, and polarization has been shown. Nevertheless …

Tumor-associated macrophages (TAMs) are the most widely infiltrating immune cells in the
tumor microenvironment (TME). Clinically, the number of TAMs is closely correlated with …

Extensive clinical and experimental evidence suggests that macrophages play a crucial role
in cancer immunotherapy. Cluster of differentiation (CD) 47, which is found on both healthy …

The identification of thrombospondin-1 as an angiogenesis inhibitor in 1990 prompted
interest in its role in cancer biology and potential as a therapeutic target. Decreased …

Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular
heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME) …